Hillevax Inc HLVX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
13.84UNCH (UNCH)
Volume
2,481
Close
13.84UNCH (UNCH)
Volume
220,246
52 week range
9.94 - 20.22
Loading...
  • Open13.95
  • Day High14.56
  • Day Low13.41
  • Prev Close13.99
  • 52 Week High20.22
  • 52 Week High Date03/04/24
  • 52 Week Low9.94
  • 52 Week Low Date10/23/23

Key Stats

  • Market Cap688.138M
  • Shares Out49.72M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta0.79
  • YTD % Change-13.77

KEY STATS

  • Open13.95
  • Day High14.56
  • Day Low13.41
  • Prev Close13.99
  • 52 Week High20.22
  • 52 Week High Date03/04/24
  • 52 Week Low9.94
  • 52 Week Low Date10/23/23
  • Market Cap688.138M
  • Shares Out49.72M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta0.79
  • YTD % Change-13.77

RATIOS/PROFITABILITY

  • EPS (TTM)-3.04
  • P/E (TTM)-4.56
  • Fwd P/E (NTM)-4.47
  • EBITDA (TTM)-152.849M
  • ROE (TTM)-59.55%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)10.65%

EVENTS

  • Earnings Date08/12/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Hillevax Inc

 

Profile

MORE
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes...
Robert Hershberg M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Sean Mcloughlin
Chief Operating Officer
Shane Maltbie CPA
Chief Financial Officer
Address
321 Harrison Ave, Suite 500
Boston, MA
02118
United States

Top Peers

SYMBOLLASTCHG%CHG
PRME
Prime Medicine Inc
5.61UNCHUNCH
ORIC
Oric Pharmaceuticals Inc
8.99UNCHUNCH
SVRA
Savara Inc
4.66UNCHUNCH
MLYS
Mineralys Therapeutics Inc
13.52UNCHUNCH
COGT
Cogent Biosciences Inc
7.56UNCHUNCH